Article

Pharmaceutical Executive

Korean Biotech Talks About U.S. Company Launch

Author(s):

Michelle Maskaly

Enzychem Lifesciences explains why the Korean biotech decided to open U.S. headquarters, as well as gives an update on their most recent clinical trials.

Enzychem Lifesciences’ Chairman and CEO, Ki-Young Sohn explains why the Korean biotech decided to open U.S. headquarters, as well as gives an update on their most recent clinical trials.

He spoke to Pharm Exec during a company event in New York City.

 

 

 

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Gen Li
Gen Li
Gen Li
Dr. Ben Zeskind
Gen Li
Dr. Ben Zeskind
Gen Li
Dr. Ben Zeskind
Related Content
Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment
August 3rd 2025

Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment

Don Tracy, Associate Editor
Gene Mack, CEO, GAIN Therapeutics, shares how growing clinician confidence and strong early experiences helped accelerate enrollment in the company’s Phase Ib Parkinson’s disease trial.
Credit: zimmytws | stock.adobe.com. Balancing profitability with affordability, redesigning supply chains for resilience, and engaging actively in trade policy discussions are no longer optional, they are strategic imperatives.
August 3rd 2025

How Can Pharma Leadership Prepare for the Current Tariff Environment and Potential Changes in 2026?

Thani Jambulingam, PhD
The 15% tariff on pharmaceutical imports from the European Union is not a short term inconvenience, it represents a structural shift in the economics of the US pharmaceutical market.
President Donald Trump
August 3rd 2025

President Trump Issues Letters to 17 Major Pharma Companies Demanding Action on Most-Favored-Nation Order

Mike Hollan
The letter states that the companies have 60 days to meet the President's requirements.
Exploring the Promise of E7386 and Lenvatinib Combination Therapy in Endometrial Carcinoma
August 3rd 2025

Exploring the Promise of E7386 and Lenvatinib Combination Therapy in Endometrial Carcinoma

Don Tracy, Associate Editor
Corina Dutcus, SVP, oncology global clinical development lead at Eisai, discusses the potential of the E7386 and lenvatinib combination to address unmet needs in second-line treatment for endometrial carcinoma patients.
Collaborating for Smarter AI Solutions in Oncology at Johnson and Johnson
August 3rd 2025

Collaborating for Smarter AI Solutions in Oncology at Johnson and Johnson

Don Tracy, Associate Editor
Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, discusses the importance of collaboration across the healthcare community to develop inclusive and effective AI solutions that enhance decision-making and patient outcomes in oncology.
Stock.adobe.com
August 3rd 2025

Developing the CAR-T Sector in Saudi Arabia

Mike Hollan
Jeff Liter, CEO of Luminary, discusses his company’s approach to CAR-T therapies and why the developing Saudi market has potential.